Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | C1S | P09871 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 5/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CBLB | Q13191 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18811614 | 1.00 | RORC (0.42) | RORCTYRTMIGD3ADORA1IDO1 | |
| SCHEMBL20389483 | 1.00 | RORC (0.42) | RORCTYRTMIGD3ADORA1IDO1 | |
| SCHEMBL22518536 | 0.92 | ADORA1 (0.47) | TYRTMIGD3ADORA1KDM1AADORA2A | |
| SCHEMBL3708334 | 0.86 | C1S (0.42) | RORCTYRTMIGD3ADORA1IDO1 | |
| SCHEMBL4769460 | 0.84 | TMIGD3 (0.41) | RORCTYRTMIGD3ADORA1IDO1 | |
| SCHEMBL31135495 | 0.81 | ADORA1 (0.41) | RORCTMIGD3ADORA1IDO1C1S | |
| SCHEMBL20389484 | 0.79 | TYR (0.40) | RORCTYRTMIGD3ADORA1IDO1 | |
| SCHEMBL2678119 | 0.77 | ADORA1 (0.46) | TMIGD3ADORA1C1SADORA2ACBLB | |
| SCHEMBL14811149 | 0.76 | TMIGD3 (0.38) | RORCTYRTMIGD3ADORA1IDO1 | |
| SCHEMBL18811612 | 0.75 | SMN1; SMN2 (0.49) | RORCTMIGD3ADORA1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018380-B2 | Heterocyclic modulators of HIF activity for treatment of disease | Boar of Regents, The University of Texas System (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140066424-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center (US) | 2014-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066424-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, HIF1A, EGLN3 | RORC 1343/4885TYR 3834/4885TMIGD3 3847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.